Efficacy of Ramipril in Therapy-resistant Hypertension

References

• Brogden R. N., Todd P. A., Sorkin E. M. Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1988; 36: 540, 6001. Brogden R. N., Todd P. A., Sorkin E. M. Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1988; 36: 540, 600
   PubMed Web of Science ®Google Scholar
• Balfour J. A., Goa K. L. Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. Drugs 1991; 42: 511, 5392. Balfour J. A., Goa K. L. Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. Drugs 1991; 42: 511, 539
   PubMed Web of Science ®Google Scholar
• Deget F., Brogden R. N. Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease. Drugs 1991; 41: 799, 8203. Deget F., Brogden R. N. Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease. Drugs 1991; 41: 799, 820
   PubMed Web of Science ®Google Scholar
• Todd P. A., Goa K. L. Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension. Drugs 1992; 43: 346, 3814. Todd P. A., Goa K. L. Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension. Drugs 1992; 43: 346, 381
   PubMed Web of Science ®Google Scholar
• Plosker G. L., Sorkin E. M. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders. Drugs 1994; 48: 227, 2525. Plosker G. L., Sorkin E. M. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders. Drugs 1994; 48: 227, 252
   PubMed Web of Science ®Google Scholar
• Wiseman L. R., McTavish D. Trandolapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs 1994; 48: 71, 906. Wiseman L. R., McTavish D. Trandolapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs 1994; 48: 71, 90
   PubMed Web of Science ®Google Scholar
• Frampton J. E., Peters D. H. Ramipril: An updated review of its therapeutic use in essential hypertension and heart failure. Drugs 1995; 49: 440, 4667. Frampton J. E., Peters D. H. Ramipril: An updated review of its therapeutic use in essential hypertension and heart failure. Drugs 1995; 49: 440, 466
   PubMed Web of Science ®Google Scholar
• Noble S., Sorkin E. M. Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. Drugs 1995; 49: 750, 7668. Noble S., Sorkin E. M. Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. Drugs 1995; 49: 750, 766
   PubMed Web of Science ®Google Scholar
• Goa K. L., Balfour J. A., Zuanetti G. Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction. Drugs 1996; 52: 564, 5889. Goa K. L., Balfour J. A., Zuanetti G. Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction. Drugs 1996; 52: 564, 588
   PubMed Web of Science ®Google Scholar
• Wagstaff A. J., Davis R., McTavish D. Fosinopril. A reappraisal of its pharmacology and therapeutic efficacy in essential hypertension. Drugs 1996; 51: 777, 79110. Wagstaff A. J., Davis R., McTavish D. Fosinopril. A reappraisal of its pharmacology and therapeutic efficacy in essential hypertension. Drugs 1996; 51: 777, 791
   PubMed Web of Science ®Google Scholar
• Eichstädt H. W., Felix R., Langer M., Gutmann M. L., Dougherty F. C., Huben H. J., Schmutzler H. Use of nuclear magnetic resonance imaging to show regression of hypertrophy with ramipril treatment. Am. J. Cardiol. 1987; 59: 98D–103D11. Eichstädt H. W., Felix R., Langer M., Gutmann M. L., Dougherty F. C., Huben H. J., Schmutzler H. Use of nuclear magnetic resonance imaging to show regression of hypertrophy with ramipril treatment. Am. J. Cardiol. 1987; 59: 98D–103D
   PubMed Web of Science ®Google Scholar
• Sheiban I., Arcaro G., Covi G., Accardi R., Zenorini C., Lechi A. Regression of cardiac hypertrophy after antihypertensive therapy with nifedipine and captopril. J. Cardiovasc. Pharmacol. 1987; 10: S187–S191, Suppl 1012. Sheiban I., Arcaro G., Covi G., Accardi R., Zenorini C., Lechi A. Regression of cardiac hypertrophy after antihypertensive therapy with nifedipine and captopril. J. Cardiovasc. Pharmacol. 1987; 10: S187–S191, Suppl 10
   PubMed Web of Science ®Google Scholar
• Asmar R. G., Pannier P., Santoni J. P., Laurent S., London G. M., Levy B. I., Safar M. E. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation 1988; 78: 941, 95013. Asmar R. G., Pannier P., Santoni J. P., Laurent S., London G. M., Levy B. I., Safar M. E. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation 1988; 78: 941, 950
   PubMed Web of Science ®Google Scholar
• Riegger G. A. J. The effects of ACE inhibitors on exercise capacity in the treatment of congestive heart failure. J. Cardiovasc. Pharmacol. 1990; 15: S41–S46, Suppl 214. Riegger G. A. J. The effects of ACE inhibitors on exercise capacity in the treatment of congestive heart failure. J. Cardiovasc. Pharmacol. 1990; 15: S41–S46, Suppl 2
   PubMed Web of Science ®Google Scholar
• Cichocka E., Wyszynska T., Januszewicz P., Kawalec W. Evaluation of the efficacy and safety of monotherapy for significant essential hypertension in adolescents with use of enalapril. Pediatr. Pol. 1995; 70: 145, 15115. Cichocka E., Wyszynska T., Januszewicz P., Kawalec W. Evaluation of the efficacy and safety of monotherapy for significant essential hypertension in adolescents with use of enalapril. Pediatr. Pol. 1995; 70: 145, 151
   PubMedGoogle Scholar
• Mayet J., Shahi M., McGrath K., Poulter N. R., Sever P. S., Foale R. A., Thom S. A. M. Left ventricular hypertrophy and QT dispersion in hypertension. Hypertension 1996; 28: 791, 79616. Mayet J., Shahi M., McGrath K., Poulter N. R., Sever P. S., Foale R. A., Thom S. A. M. Left ventricular hypertrophy and QT dispersion in hypertension. Hypertension 1996; 28: 791, 796
   PubMed Web of Science ®Google Scholar
• Lumme J. A. J., Jounela A. J. Left ventricular mass, serum electrolyte levels and cardiac arrhythmias in patients with mild hypertension treated with cilazapril or hydrochlorothiazide. Int. J. Cardiol. 1993; 42: 71, 7817. Lumme J. A. J., Jounela A. J. Left ventricular mass, serum electrolyte levels and cardiac arrhythmias in patients with mild hypertension treated with cilazapril or hydrochlorothiazide. Int. J. Cardiol. 1993; 42: 71, 78
   PubMed Web of Science ®Google Scholar
• Ferguson R. K., Vlasses P. H., Koplin J. R., Shirinian A., Burke J. F., Jr, Alexander J. C. Captopril in severe treatment-resistant hypertension. Am. Heart. J. 1980; 99: 579, 58518. Ferguson R. K., Vlasses P. H., Koplin J. R., Shirinian A., Burke J. F., Jr, Alexander J. C. Captopril in severe treatment-resistant hypertension. Am. Heart. J. 1980; 99: 579, 585
   PubMed Web of Science ®Google Scholar
• Havelka J., Boerlin H. J., Studer A., Greminger P., Tenschert W., Luescher T., Siegenthaler W., Vetter W., Walger P., Vetter H. Long-term experience with captopril in severe hypertension. Br. J. Clin. Pharmacol. 1982; 14: 71S–76S19. Havelka J., Boerlin H. J., Studer A., Greminger P., Tenschert W., Luescher T., Siegenthaler W., Vetter W., Walger P., Vetter H. Long-term experience with captopril in severe hypertension. Br. J. Clin. Pharmacol. 1982; 14: 71S–76S
   PubMed Web of Science ®Google Scholar
• Raine A. E. G., Ledingham J. G. G. Clinical experience with captopril in the treatment of severe drug-resistant hypertension. Am. J. Cardiol. 1982; 49: 1475, 147920. Raine A. E. G., Ledingham J. G. G. Clinical experience with captopril in the treatment of severe drug-resistant hypertension. Am. J. Cardiol. 1982; 49: 1475, 1479
   PubMed Web of Science ®Google Scholar
• Chrysant S. G., Bal I. S., Johnson B., McPherson M. A comparative study of captopril and enalapril in patients with severe hypertension. J. Clin. Pharmacol. 1985; 25: 149, 15121. Chrysant S. G., Bal I. S., Johnson B., McPherson M. A comparative study of captopril and enalapril in patients with severe hypertension. J. Clin. Pharmacol. 1985; 25: 149, 151
   PubMed Web of Science ®Google Scholar
• Kocijancic M., Dimkovic S. Antihypertensive effect of indapamide given in conjunction with captopril in severe hypertension. Curr. Med. Res. Opin. 1986; 10: 313, 31822. Kocijancic M., Dimkovic S. Antihypertensive effect of indapamide given in conjunction with captopril in severe hypertension. Curr. Med. Res. Opin. 1986; 10: 313, 318
   PubMed Web of Science ®Google Scholar
• Schrader J., Schoel G., Scheler F. Ergebnisse einer 5-Jahres-Studie mit Captopril bei Patienten mit schwerer therapieresistenter Hypertonie. Klin. Wochenschr. 1986; 64: 695, 70023. Schrader J., Schoel G., Scheler F. Ergebnisse einer 5-Jahres-Studie mit Captopril bei Patienten mit schwerer therapieresistenter Hypertonie. Klin. Wochenschr. 1986; 64: 695, 700
   PubMedGoogle Scholar
• Agabiti-Rosei E., Ambrosioni E., Dal Palu C., Muiesan M. L., Zanchetti A. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study. J. Hypertension 1995; 13: 1325, 133424. Agabiti-Rosei E., Ambrosioni E., Dal Palu C., Muiesan M. L., Zanchetti A. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study. J. Hypertension 1995; 13: 1325, 1334
   PubMed Web of Science ®Google Scholar
• Lievre M., Gueret P., Gayet C., Roudaut R., Haugh M. C., Delair S., Boissel J. P. Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. Hypertension 1995; 25: 92, 9725. Lievre M., Gueret P., Gayet C., Roudaut R., Haugh M. C., Delair S., Boissel J. P. Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. Hypertension 1995; 25: 92, 97
   PubMed Web of Science ®Google Scholar
• Myburgh D. P., Verho M., Botes J. H., Erasmus T. P., Luus H. G. 24-hour blood pressure control with ramipril: comparison of once-daily morning and evening administration. Curr. Ther. Res. 1995; 56: 1298, 130626. Myburgh D. P., Verho M., Botes J. H., Erasmus T. P., Luus H. G. 24-hour blood pressure control with ramipril: comparison of once-daily morning and evening administration. Curr. Ther. Res. 1995; 56: 1298, 1306
   Web of Science ®Google Scholar
• Kaplan N. M. The CARE study: A postmarketing evaluation of ramipril in 11, 100 patients. Clin. Ther. 1996; 18: 658, 67027. Kaplan N. M. The CARE study: A postmarketing evaluation of ramipril in 11, 100 patients. Clin. Ther. 1996; 18: 658, 670
   PubMed Web of Science ®Google Scholar
• Yasky J., Verho M., Erasmus T. P., Luus H. G., Angela M., Grandin L., Akbary M. A., Rangoonwala B. Efficacy of ramipril versus enalapril in patients with mild to moderate essential hypertension. Br. J. Clin. Pract. 1996; 50: 302, 31028. Yasky J., Verho M., Erasmus T. P., Luus H. G., Angela M., Grandin L., Akbary M. A., Rangoonwala B. Efficacy of ramipril versus enalapril in patients with mild to moderate essential hypertension. Br. J. Clin. Pract. 1996; 50: 302, 310
   PubMedGoogle Scholar
• Kothe K., Diel M., Ullmann K., Lehmann H. Risk score modification during complex treatment in congestive heart failure in the elderly -comparison of captopril and ramipril. Perfusion 1996; 9: 198, 20029. Kothe K., Diel M., Ullmann K., Lehmann H. Risk score modification during complex treatment in congestive heart failure in the elderly -comparison of captopril and ramipril. Perfusion 1996; 9: 198, 200
   Web of Science ®Google Scholar
• Willenbrock R., Özcelik C., Osterziel K. J., Dietz R. Angiotensin-converting enzyme inhibition, autonomic activity, and hemodynamics in patients with heart failure who perform isometric exercise. Am. Heart J. 1996; 131: 999, 100630. Willenbrock R., Özcelik C., Osterziel K. J., Dietz R. Angiotensin-converting enzyme inhibition, autonomic activity, and hemodynamics in patients with heart failure who perform isometric exercise. Am. Heart J. 1996; 131: 999, 1006
   PubMed Web of Science ®Google Scholar
• Heintz B., Verho M., Theobald K. H., Frampton H. Efficacy and safety of ramipril in long-term treatment of congestive heart failure. Curr. Ther. Res. 1994; 55: 489, 49931. Heintz B., Verho M., Theobald K. H., Frampton H. Efficacy and safety of ramipril in long-term treatment of congestive heart failure. Curr. Ther. Res. 1994; 55: 489, 499
   Web of Science ®Google Scholar
• Sigurdsson A., Amtorp O., Gundersen T., Nilsson B., Remes J., Swedberg K. Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. Br. Heart J., 72: 422, 42732. Sigurdsson A., Amtorp O., Gundersen T., Nilsson B., Remes J., Swedberg K. Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. Br. Heart J., 72: 422, 427
   PubMedGoogle Scholar
• Heintz B., Verho M., Brockmeier D., Kirsten R., Nelson K., Rangoonwala B., Maigatter S., Lückel G., Kierdorf H., Sieberth H. G. Influence of ramipril on plasma atrial natriuretic peptide, antidiuretic hormone, angiotensin I1 and aldosterone in patients with chronic congestive heart failure. Clin. Physiol. Biochem. 1992; 9: 113, 11833. Heintz B., Verho M., Brockmeier D., Kirsten R., Nelson K., Rangoonwala B., Maigatter S., Lückel G., Kierdorf H., Sieberth H. G. Influence of ramipril on plasma atrial natriuretic peptide, antidiuretic hormone, angiotensin I1 and aldosterone in patients with chronic congestive heart failure. Clin. Physiol. Biochem. 1992; 9: 113, 118
   PubMedGoogle Scholar
• Kholeif M. A., Pringle S., Kesson E., Murray G., Kennedy J. A., Lorimer A. R., Stock J. K., Brown J. J. A comparison of the efficacy and safety of ramipril and digoxin added to maintenance diuretic treatment in patients with chronic heart failure. J. Cardiovasc. Pharmacol. 1991; 18: S180–S183, Suppl 234. Kholeif M. A., Pringle S., Kesson E., Murray G., Kennedy J. A., Lorimer A. R., Stock J. K., Brown J. J. A comparison of the efficacy and safety of ramipril and digoxin added to maintenance diuretic treatment in patients with chronic heart failure. J. Cardiovasc. Pharmacol. 1991; 18: S180–S183, Suppl 2
   PubMed Web of Science ®Google Scholar
• Hall A. S., Winter C., Bogie S. M., Mackintosh A. F., Murray G. D., Ball S. G. The Acute Infarction Ramipril Efficacy (AIRE) Study: rationale, design, organization, and outcome definitions. J. Cardiovasc. Pharmacol. 1991; 18: S105–S109, Suppl 235. Hall A. S., Winter C., Bogie S. M., Mackintosh A. F., Murray G. D., Ball S. G. The Acute Infarction Ramipril Efficacy (AIRE) Study: rationale, design, organization, and outcome definitions. J. Cardiovasc. Pharmacol. 1991; 18: S105–S109, Suppl 2
   PubMed Web of Science ®Google Scholar
• Meisel S., Shamiss A., Verho M. T., Rosenthal T. Ramipril in the treatment of severe hypertension: Pharmacokinetics and clinical efficacy. Curr Ther. Res. 1991; 6: 998, 100336. Meisel S., Shamiss A., Verho M. T., Rosenthal T. Ramipril in the treatment of severe hypertension: Pharmacokinetics and clinical efficacy. Curr Ther. Res. 1991; 6: 998, 1003
   Google Scholar
• Lederle R. M., Klaus D., Verho M. Ramipril. Ein neuer Angiotensin-Konversions-Enzym-Inhibitor in der Behandlung der schweren, therapie-resistenten Hypertonie. Munch. Med. Wochenschr. 1991; 133: 394, 39637. Lederle R. M., Klaus D., Verho M. Ramipril. Ein neuer Angiotensin-Konversions-Enzym-Inhibitor in der Behandlung der schweren, therapie-resistenten Hypertonie. Munch. Med. Wochenschr. 1991; 133: 394, 396
   Google Scholar
• Lewis J. A., Jones D. R., Röhmel J. Biostatistical methodology in clinical trials - a European guideline. Stat. Med. 1995; 14: 1655, 165738. Lewis J. A., Jones D. R., Röhmel J. Biostatistical methodology in clinical trials - a European guideline. Stat. Med. 1995; 14: 1655, 1657
   PubMed Web of Science ®Google Scholar
• Büning H., Trenkler G. Nichtparametrische Statistische Methoden. de Gruyter, Berlin 197839. Büning H., Trenkler G. Nichtparametrische Statistische Methoden. de Gruyter, Berlin 1978
   Google Scholar
• Sachs L. Angewandte Statistik. Springer-Verlag, Heidelberg 199740. Sachs L. Angewandte Statistik. Springer-Verlag, Heidelberg 1997
   Google Scholar
• Cohen M. C., Rohtla K. M., Lavery C. E., Muller J. E., Mittleman M. A. Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am. J. Cardiol. 1997; 79: 1512, 151641. Cohen M. C., Rohtla K. M., Lavery C. E., Muller J. E., Mittleman M. A. Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am. J. Cardiol. 1997; 79: 1512, 1516
   PubMed Web of Science ®Google Scholar
• Kaplan N. M. Southwest Internal Medicine Conference: Difficult-to-treat hypertension. Am. J. Med. Sci. 1995; 309: 339, 34642. Kaplan N. M. Southwest Internal Medicine Conference: Difficult-to-treat hypertension. Am. J. Med. Sci. 1995; 309: 339, 346
   PubMed Web of Science ®Google Scholar
• Alderman M. H., Budner N., Cohen H., Lamport B., Ooi W. L. Prevalence of drug resistant hypertension. Hypertensiou 1988; 11: 1171–1175, (Suppl 2)43. Alderman M. H., Budner N., Cohen H., Lamport B., Ooi W. L. Prevalence of drug resistant hypertension. Hypertensiou 1988; 11: 1171–1175, (Suppl 2)
   Google Scholar
• Simunic M., Rumboldt Z., Ljutic D., Sardelic S. Ramipril decreases chlorthalidone-induced loss of magnesium and potassium in hypertensive patients. J. Clin. Pharmacol. 1995; 35: 1150, 115544. Simunic M., Rumboldt Z., Ljutic D., Sardelic S. Ramipril decreases chlorthalidone-induced loss of magnesium and potassium in hypertensive patients. J. Clin. Pharmacol. 1995; 35: 1150, 1155
   PubMed Web of Science ®Google Scholar
• Aberg H., Morlin C., Lithell H. Different long-term metabolic effects of enalapril and atenolol in patients with mild hypertension. J. Hum. Hypertension 1995; 9: 149, 15345. Aberg H., Morlin C., Lithell H. Different long-term metabolic effects of enalapril and atenolol in patients with mild hypertension. J. Hum. Hypertension 1995; 9: 149, 153
   PubMed Web of Science ®Google Scholar
• Howes L. G., Lykos D., Rennie G. C. Effects of antihypertensive drugs on coronary artery disease risk: A meta-analysis. Clin. Expl. Pharmacol. Physiol. 1996; 23: 555, 55846. Howes L. G., Lykos D., Rennie G. C. Effects of antihypertensive drugs on coronary artery disease risk: A meta-analysis. Clin. Expl. Pharmacol. Physiol. 1996; 23: 555, 558
   PubMed Web of Science ®Google Scholar
• Brandt D. Treatment of arterial hypertension with ramipril. Results of the Austrian Ramipril Trial (ART I) - an open multicentre general practice study. Clin. Drug Invest. 1996; 12: 8, 1547. Brandt D. Treatment of arterial hypertension with ramipril. Results of the Austrian Ramipril Trial (ART I) - an open multicentre general practice study. Clin. Drug Invest. 1996; 12: 8, 15
   Web of Science ®Google Scholar
• Cavazzini D., Amadei C., Manfredini R., Musacci G., Mele D., Longhini C. Effect of acute and long-term administration of ramipril on circadian rhythm of blood pressure in essential hypertension. Advan. Ther. 1995; 12: 11, 2148. Cavazzini D., Amadei C., Manfredini R., Musacci G., Mele D., Longhini C. Effect of acute and long-term administration of ramipril on circadian rhythm of blood pressure in essential hypertension. Advan. Ther. 1995; 12: 11, 21
   PubMed Web of Science ®Google Scholar
• Blomer A., Luders S., Brunner G., Schoel G., Schrader J. Vergleichende Untersuchung der 24-Stunden-Blutdruckwirksamkeit der ACE-Hemmer Ramipril und Captopril bei Patienten mit essentieller Hypertonie. Nieren. Hochdruck. 1996; 25: 392, 39449. Blomer A., Luders S., Brunner G., Schoel G., Schrader J. Vergleichende Untersuchung der 24-Stunden-Blutdruckwirksamkeit der ACE-Hemmer Ramipril und Captopril bei Patienten mit essentieller Hypertonie. Nieren. Hochdruck. 1996; 25: 392, 394
   Google Scholar